ATE300947T1 - Behandlung von erkrankungen mit zystenbildung - Google Patents

Behandlung von erkrankungen mit zystenbildung

Info

Publication number
ATE300947T1
ATE300947T1 AT99966268T AT99966268T ATE300947T1 AT E300947 T1 ATE300947 T1 AT E300947T1 AT 99966268 T AT99966268 T AT 99966268T AT 99966268 T AT99966268 T AT 99966268T AT E300947 T1 ATE300947 T1 AT E300947T1
Authority
AT
Austria
Prior art keywords
treatment
diseases involving
cyst formation
diagnosis
involving cyst
Prior art date
Application number
AT99966268T
Other languages
English (en)
Inventor
George F Schreiner
Alison Joly
R Tyler White
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE300947T1 publication Critical patent/ATE300947T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948Sedatives, e.g. cannabinoids, barbiturates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99966268T 1998-12-18 1999-12-15 Behandlung von erkrankungen mit zystenbildung ATE300947T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11300898P 1998-12-18 1998-12-18
US13620899P 1999-05-26 1999-05-26
PCT/US1999/029763 WO2000037085A1 (en) 1998-12-18 1999-12-15 Treatment of diseases involving cyst formation

Publications (1)

Publication Number Publication Date
ATE300947T1 true ATE300947T1 (de) 2005-08-15

Family

ID=26810615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966268T ATE300947T1 (de) 1998-12-18 1999-12-15 Behandlung von erkrankungen mit zystenbildung

Country Status (7)

Country Link
US (2) US6380183B1 (de)
EP (1) EP1140106B1 (de)
AT (1) ATE300947T1 (de)
AU (1) AU2185000A (de)
DE (1) DE69926535T2 (de)
ES (1) ES2246588T3 (de)
WO (1) WO2000037085A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100829297B1 (ko) * 2000-07-31 2008-05-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 2-아릴-8-옥소디히드로푸린 유도체를 유효성분으로 하는치매증 치료제
EP2035038A4 (de) * 2006-04-03 2011-04-06 Stowers Inst For Medical Res Zusammensetzungen und verfahren zur behandlung von polyzystischer nierenerkrankung
US8429516B1 (en) * 2007-08-20 2013-04-23 Adobe Systems Incorporated Media player feedback
US20100028416A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
WO2011050471A1 (en) * 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
EP3037518B1 (de) 2014-12-28 2020-05-06 Femtobiomed Inc. Vorrichtung zum einbringen von material in eine zelle
WO2019222559A1 (en) * 2018-05-16 2019-11-21 University Of Washington High-throughput automation of organoids for identifying therapeutic strategies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) * 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2599740B1 (fr) 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2659329B1 (fr) * 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5789189A (en) 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
AU5140193A (en) 1992-09-25 1994-04-26 Regents Of The University Of California, The Inhibition of cyst formation by cytoskeletal specific drugs
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5776946A (en) * 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
FR2785803B1 (fr) * 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
CA2406901A1 (en) * 2000-01-14 2001-07-19 Mitokor Identification of peripheral benzodiazepine receptor binding agents

Also Published As

Publication number Publication date
US6380183B1 (en) 2002-04-30
DE69926535T2 (de) 2006-03-30
EP1140106B1 (de) 2005-08-03
AU2185000A (en) 2000-07-12
ES2246588T3 (es) 2006-02-16
WO2000037085A1 (en) 2000-06-29
US20030008864A1 (en) 2003-01-09
DE69926535D1 (de) 2005-09-08
EP1140106A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
EA200100822A1 (ru) Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BR9912053A (pt) Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DK0841949T3 (da) Anvendelse af saccharid-konjugater
ATE355288T1 (de) Verbindungen und therapeutische methoden
PT815087E (pt) Derivados de fenilo trissubstituidos
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
PL350408A1 (en) Antithrombotic use of glycine betaine
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
ATE300947T1 (de) Behandlung von erkrankungen mit zystenbildung
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
TR200200278T2 (tr) Kalsilitik bileşimler
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
NO20005548L (no) Mykobakterieinhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties